- Home
- SGMT vs CIA Comparison
SGMT vs CIA Comparison
Compare SGMT & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- CIA
- Stock Information
- Founded
- SGMT 2006
- CIA 1969
- Country
- SGMT United States
- CIA United States
- Employees
- SGMT N/A
- CIA N/A
- Industry
- SGMT
- CIA Life Insurance
- Sector
- SGMT
- CIA Finance
- Exchange
- SGMT Nasdaq
- CIA Nasdaq
- Market Cap
- SGMT 238.7M
- CIA 286.2M
- IPO Year
- SGMT 2023
- CIA N/A
- Fundamental
- Price
- SGMT $7.39
- CIA $5.56
- Analyst Decision
- SGMT Strong Buy
- CIA
- Analyst Count
- SGMT 8
- CIA 0
- Target Price
- SGMT $29.75
- CIA N/A
- AVG Volume (30 Days)
- SGMT 570.9K
- CIA 103.3K
- Earning Date
- SGMT 11-13-2025
- CIA 11-06-2025
- Dividend Yield
- SGMT N/A
- CIA N/A
- EPS Growth
- SGMT N/A
- CIA N/A
- EPS
- SGMT N/A
- CIA 0.21
- Revenue
- SGMT N/A
- CIA $247,020,000.00
- Revenue This Year
- SGMT N/A
- CIA $4.22
- Revenue Next Year
- SGMT N/A
- CIA $4.46
- P/E Ratio
- SGMT N/A
- CIA $27.23
- Revenue Growth
- SGMT N/A
- CIA N/A
- 52 Week Low
- SGMT $1.73
- CIA $2.90
- 52 Week High
- SGMT $11.41
- CIA $6.36
- Technical
- Relative Strength Index (RSI)
- SGMT 44.02
- CIA 43.75
- Support Level
- SGMT $7.21
- CIA $5.12
- Resistance Level
- SGMT $8.84
- CIA $5.77
- Average True Range (ATR)
- SGMT 0.62
- CIA 0.45
- MACD
- SGMT -0.09
- CIA -0.04
- Stochastic Oscillator
- SGMT 19.69
- CIA 24.19
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.